The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
High-Level Cefixime- and Ceftriaxone-Resistant Neisseria gonorrhoeae in France: Novel penA Mosaic Allele in a Successful International Clone Causes Treatment Failure
Open accessAbstract
Recently, the first Neisseria gonorrhoeae strain (H041) highly resistant to the expanded-spectrum cephalosporins (ESCs) ceftriaxone and cefixime, which are the last remaining options for first-line gonorrhea treatment, was isolated in Japan. Here, we confirm and characterize a second strain (F89) with high-level cefixime and ceftriaxone resistance which was isolated in France and most likely caused a treatment failure with cefixime. F89 was examined using six species-confirmatory tests, antibiograms (33 antimicrobials),porB sequencing,N. gonorrhoeae multiantigen sequence typing (NG-MAST), multilocus sequence typing (MLST), and sequencing of known gonococcal resistance determinants (penA,mtrR,penB,ponA, and pilQ). F89 was assigned to MLST sequence type 1901 (ST1901) and NG-MAST ST1407, which is a successful gonococcal clone that has spread globally. F89 has high-level resistance to cefixime (MIC = 4 μg/ml) and ceftriaxone (MIC = 1 to 2 μg/ml) and resistance to most other antimicrobials examined. A novel penA mosaic allele (penA-CI), which was penA-XXXIV with an additional A501P alteration in penicillin-binding protein 2, was the primary determinant for high-level ESC resistance, as determined by transformation into a set of recipient strains.N. gonorrhoeae appears to be emerging as a superbug, and in certain circumstances and settings, gonorrhea may become untreatable. Investigations of the biological fitness and enhanced understanding and monitoring of the ESC-resistant clones and their international transmission are required. Enhanced disease control activities, antimicrobial resistance control and surveillance worldwide, and public health response plans for global (and national) perspectives are also crucial. Nevertheless, new treatment strategies and/or drugs and, ideally, a vaccine are essential to develop for efficacious gonorrhea management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical and Laboratory Standards Institute
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300416 · Cited by 5,091
Ohnishi, M., Golparian, D., Shimuta, K., Saika, T., Hoshina, S., Iwasaku, K., Nakayama, S.-I., Kitawaki, J., & Unemo, M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00325-11 · Cited by 686
Self-citationHagman, K. E., Spratt, B. G., Balthazar, J. T., Pan, W., Judd, R. C., & Shafer, W. M. (1995) · Microbiology · doi:10.1099/13500872-141-3-611 · Cited by 368
Tapsall, J. W., Ndowa, F., Lewis, D. A., & Unemo, M. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.63 · Cited by 297
Self-citationCeftriaxone-Resistant Neisseria gonorrhoeae , Japan
Ohnishi, M., Saika, T., Hoshina, S., Iwasaku, K., Nakayama, S.-I., Watanabe, H., & Kitawaki, J. (2011) · Emerging Infectious Diseases · doi:10.3201/eid1701.100397 · Cited by 236
Self-citationUnemo, M., Fasth, O., Fredlund, H., Limnios, A., & Tapsall, J. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp098 · Cited by 226
Self-citationAmeyama, S., Onodera, S., Takahata, M., Minami, S., Maki, N., Endo, K., Goto, H., Suzuki, H., & Oishi, Y. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.12.3744-3749.2002 · Cited by 222
Lindberg, R., Fredlund, H., Nicholas, R. A., & Unemo, M. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01604-06 · Cited by 212
Self-citationRopp, P. A., Hu, M. Y., Olesky, M., & Nicholas, R. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.3.769-777.2002 · Cited by 206
Self-citationIto, M., Deguchi, T., Mizutani, K.-S., Yasuda, M., Yokoi, S., Ito, S.-I., Takahashi, Y., Ishihara, S., Kawamura, Y., & Ezaki, T. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.1.137-143.2005 · Cited by 205
Cited by
Molecular mechanisms of antibiotic resistance
Blair, J. M. A., Webber, M. A., Baylay, A. J., Ogbolu, D. O., & Piddock, L. J. V. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3380 · Cited by 4,092
Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Sexually transmitted diseases treatment guidelines (2015)
Workowski, K., & BOLAN, G. A. (2015) · Reproductive Endocrinology · doi:10.18370/2309-4117.2015.24.51-56 · Cited by 2,698
Understanding the mechanisms and drivers of antimicrobial resistance
Holmes, A. H., Moore, L. S. P., Sundsfjord, A., Steinbakk, M., Regmi, S., Karkey, A., Guerin, P. J., & Piddock, L. J. V. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00473-0 · Cited by 2,611
Sexually Transmitted Diseases Treatment Guidelines, 2010
(2011) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2011.04.006 · Cited by 2,076
Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future
Unemo, M., & Shafer, W. M. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00010-14 · Cited by 1,151
Self-citationSexually transmitted infections: challenges ahead
Unemo, M., Bradshaw, C. S., Hocking, J. S., de Vries, H. J. C., Francis, S. C., Mabey, D., Marrazzo, J. M., Sonder, G. J. B., Schwebke, J. R., Hoornenborg, E., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30310-9 · Cited by 751
Self-citationEllington, M. J., Ekelund, O., Aarestrup, F. M., Canton, R., Doumith, M., Giske, C., Grundman, H., Hasman, H., Holden, M. T. G., Hopkins, K. L., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.11.012 · Cited by 603
Wi, T., Lahra, M. M., Ndowa, F., Bala, M., Dillon, J.-A. R., Ramon-Pardo, P., Eremin, S. R., Bolan, G., & Unemo, M. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002344 · Cited by 600
Self-citationUnemo, M., Seifert, H. S., Hook, E. W., Hawkes, S., Ndowa, F., & Dillon, J.-A. R. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0128-6 · Cited by 524
Self-citation2012 European guideline on the diagnosis and treatment of gonorrhoea in adults
Bignell, C., Unemo, M., The European STI Guidelines Editorial Board, Radcliffe, K., Jensen, J. S., Babayan, K., Barton, S., Cusini, M., Gomberg, M., Janier, M., et al. (2013) · International Journal of STD & AIDS · doi:10.1177/0956462412472837 · Cited by 483
Self-citationAntimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum
Huttner, A., Harbarth, S., Carlet, J., Cosgrove, S., Goossens, H., Holmes, A., Jarlier, V., Voss, A., Pittet, D., & participants, F. T. W. H.-A. I. F. (2013) · Antimicrobial Resistance and Infection Control · doi:10.1186/2047-2994-2-31 · Cited by 447
Emergence of Multidrug-Resistant, Extensively Drug-Resistant and Untreatable Gonorrhea
Unemo, M., & Nicholas, R. A. (2012) · Future Microbiology · doi:10.2217/fmb.12.117 · Cited by 421
Self-citationCurrent Epidemiology and Growing Resistance of Gram-Negative Pathogens
Livermore, D. M. (2012) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2012.27.2.128 · Cited by 417
Eyre, D. W., Sanderson, N. D., Lord, E., Regisford-Reimmer, N., Chau, K., Barker, L., Morgan, M., Newnham, R., Golparian, D., Unemo, M., et al. (2018) · Eurosurveillance · doi:10.2807/1560-7917.es.2018.23.27.1800323 · Cited by 348
Self-citationCamara, J., Serra, J., Ayats, J., Bastida, T., Carnicer-Pont, D., Andreu, A., & Ardanuy, C. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks162 · Cited by 339
Unemo, M., Golparian, D., Sánchez-Busó, L., Grad, Y., Jacobsson, S., Ohnishi, M., Lahra, M. M., Limnios, A., Sikora, A. E., Wi, T., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw288 · Cited by 297
Self-citationUnemo, M., Lahra, M. M., Cole, M., Galarza, P., Ndowa, F., Martin, I., Dillon, J.-A. R., Ramon-Pardo, P., Bolan, G., & Wi, T. (2019) · Sexual Health · doi:10.1071/sh19023 · Cited by 262
Self-citationMechanisms of Action of Carbapenem Resistance
Aurilio, C., Sansone, P., Barbarisi, M., Pota, V., Giaccari, L. G., Coppolino, F., Barbarisi, A., Passavanti, M. B., & Pace, M. C. (2022) · Antibiotics · doi:10.3390/antibiotics11030421 · Cited by 260
(2013) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2012.10.014 · Cited by 259
Kirkcaldy, R. D., Harvey, A., Papp, J. R., del Rio, C., Soge, O. O., Holmes, K. K., Hook, E. W., Kubin, G., Riedel, S., Zenilman, J., et al. (2016) · MMWR Surveillance Summaries · doi:10.15585/mmwr.ss6507a1 · Cited by 249
Lahra, M. M., Martin, I., Demczuk, W., Jennison, A. V., Lee, K.-I., Nakayama, S.-I., Lefebvre, B., Longtin, J., Ward, A., Mulvey, M. R., et al. (2018) · Emerging Infectious Diseases · doi:10.3201/eid2404.171873 · Cited by 239
Self-citationKirkcaldy, R. D., Zaidi, A., Hook, E. W., Holmes, K. K., Soge, O., del Rio, C., Hall, G., Papp, J., Bolan, G., & Weinstock, H. S. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-5-201303050-00004 · Cited by 115
Jean, S., Juneau, R. A., Criss, A. K., & Cornelissen, C. N. (2016) · Infection and Immunity · doi:10.1128/iai.00319-16 · Cited by 63
van der Veen, S. (2023) · Infectious Microbes and Diseases · doi:10.1097/im9.0000000000000113 · Cited by 49
Maurakis, S., Keller, K., Maxwell, C. N., Pereira, K., Chazin, W. J., Criss, A. K., & Cornelissen, C. N. (2019) · PLOS Pathogens · doi:10.1371/journal.ppat.1007937 · Cited by 45
Metadata
- Authors
- Unemo, M., Golparian, D., Nicholas, R., Ohnishi, M., Gallay, A., & Sednaoui, P.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2012-03
- Volume
- 56
- Issue
- 3
- Pages
- 1273-1280
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2123386797
- Cited by
- 653
- References
- 40
- FWCI
- 20.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.